One-step thickness shear mode acoustic assay for plasminogen activators

A new procedure is presented for the measurement of plasminogen activators using a thickness shear mode sensor and a modified version of the fibrin plate assay at the micro-scale. Separate, well-mixed solutions of the substrates fibrinogen and plasminogen, and enzymes thrombin and the plasminogen activator sample were mixed together and placed on the sensor surface. The temperature and evaporation were controlled during the assay. The clot dissolution time correlated well with the quantity of the plasminogen activator in the sample. The average relative standard deviation was 12.5%.     

Simplex optimization of acoustic assay for plasminogen activators

This article discusses the optimization of a newly developed method for measuring the activity of plasminogen activators using a thickness-shear-mode acoustic sensor. A variable-size simplex algorithm was used for optimization. Preliminary tests were performed to design the first simplex. A desirability function was defined to translate each performance value to a membership value of 0 to 1. If there was more than one performance variable, their membership values were translated to an aggregated membership value using another function that considers their individual influence on sensor performance. Two rounds of optimization were carried out for streptokinase followed by a single optimization for tissue-type plasminogen activator. In the last optimization, ratios of control variables were used in order to reduce the number of parameters and to formulate easily adjustable assay conditions. The results showed the usefulness of the simplex method for optimizing this type of assay, and the importance of preliminary tests and prior knowledge in providing rapid convergence using fewer experiments. The optimized plasminogen activator assay can be considered a reference method for measurement of all members of this drug class.     

Large-scale preparation of the Δ10 form of staphylokinase by in vitro processing of recombinant staphylokinase with purified human plasminogen

The authors have developed a rapid and convenient method for purification of a low molecular weight form (Δ10) of the bacterial plasminogen activator, staphylokinase. Recombinant staphylokinase is expressed inEscherichia coli, with an amino terminal extension that facilitated purification by immobilized metal-affinity chromatography. Purified staphylokinase is treated with human plasminogen, and the resulting truncated form is purified using a combination of immobilized metal affinity chromatography and hydrophobic interaction chromatography. Purified protein is characterized by amino terminal sequencing and in vitro plasminogen activation assay.     

Venous thrombolysis by tissue-type plasminogen activator in conjunction with the urokinase-fibrinogen covalent conjugate

Conjunctive administration of the tissue-type plasminogen activator (t-PA) and the urokinase-fibrinogen covalent conjugate (UK-Fbg) was studied by the example of venous thrombosis in dogs. Comparing the effect of separate use of the two components, we observed the potentiation of thrombolytic effect induced by an iv bolus infusion administration of the tissue-type plasminogen activator (1 and 4 mg, respectively) combined with a bolus administration 15 min after the first injection of the 25,000 IU UK-Fbg. Faster-action and potentiation effects of thromboysis were observed with the same administration scheme when the t-PA was used as bolus infusion (1 and 1 mg, respectively) combined wiht a bolus of the 250,000 IU fibrinogen-modified urokinase. The findings indicate an approach to the development of efficient thrombolytic compositions.     

In vitro comparison of complementary interactions between synthetic linear/branched oligo/poly-L-lysines and tissue plasminogen activator by means of high-performance monolithic-disk affinity chromatography

The recently discovered serine protease called tissue plasminogen activator (t-PA) enables efficient dissolution of blood clots. t-PA works by converting plasminogen into its active form, plasmin, dissolving the major component of blood clots, fibrin. The activation of plasminogen by t-PA is enhanced by the presence of fibrin, and this is probably due to the fact that both plasminogen and t-PA possess high affinity binding sites for fibrin. Besides fibrin, fibrin monomers and some fibrin(ogen) degradation products, certain synthetic polymers (for instance, poly-L-lysines) can provide the same stimulation of plasminogen activation. The recently developed high-performance monolithic-disk chromatography, HPMDC, could become the most convenient way to study biological pairs of interest. The inherent speed of HPMDC isolation facilitates the recovery of a biologically active product, since the exposure to putative denaturing influences, such as solvents or temperature, is reduced. The better mass transfer mechanism (convection rather than diffusion) allows to consider only the biospecific reaction as time limiting. The step-by-step modeling of hypothetical affinity pairs between t-PA and different types of oligo/polymer forms of linear and branched lysine derivatives obtained both by initiated polycondensation and solid-phase peptide synthesis using HPMDC seemed to be possible and a quite useful tool. The results of quantitative evaluation of such affinity interactions were compared with those established for natural affinity counterparts to t-PA (monoclonal antibodies, plasminogen, fibrinogen). The role of steric structure of lysine ligands was observed and analyzed. The results allowing to make the practical choice of affinity systems will be used for development of fast and efficient analytical and preparative methods for the downstream processes of recombinant production of this valuable enzyme.     

Fibrinolytic effect of tissue plasminogen activator on cerebral embolism in stroke-prone spontaneously hypertensive rats.

To study the thrombolytic effect of tissue plasminogen activator (t-PA) on cerebral emboli, we characterized cerebral embolization in stroke-prone spontaneously hypertensive rats (SHRSPs) and Wistar Kyoto rats (WKYs). [125I]Fibrin clot particles (20-100 microns diameter) were injected twice at an interval of 90 min into the left internal carotid artery of WKYs and SHRSPs. After each injection, spontaneous embolus dissolution was monitored with a gamma-ray detector placed on the head of the embolic rats. Embolus dissolution was spontaneously generated in 15 min after the injection of fibrin clots. In WKYs, 21% and 42% of the clots were dissolved 30 and 90 min after the second embolization, respectively. On the other hand, the spontaneous embolus dissolution in SHRSPs was significantly lower than that of WKYs, indicating that the endogenous fibrinolytic ability of SHRSPs is less potent than that of normotensive rats. The intravenous administration of t-PA at doses of 75, 250 and 750 micrograms/kg caused a dose-dependent embolus dissolution in SHRSPs. Furthermore, systematically applied t-PA produced embolus dissolution without causing systemic plasminogen activation, fibrinogen breakdown or bleeding. In conclusion, the intravenous administration of t-PA produces selective embolus dissolution without systemic fibrino(geno)lysis in a cerebral embolic SHRSP.     

Prediction of the three-dimensional structure of the enzymatic domain of t-PA

Summary Tissue plasminogen activator (t-PA), an enzyme of the fibrinolytic system, is responsible for lysis of fibrin via activation of plasminogen, and therefore for degradation of blood clots. There are currently no X-ray crystal structure data of the t-PA molecule available either in whole or in part. We therefore predicted the three-dimensional structure of the protease domain by means of computer-graphical methods.The model obtained forms a basis for understanding the binding of plasminogen to the active site of t-PA. In addition, the interactions of various inhibitors with t-PA were studied by modeling them into the active site. The model also yields an explanation for the observed amidolytic activity of t-PA in the single chain form.     

Development of a thickness shear mode acoustic sensor based on an electrosynthesized molecularly imprinted polymer using an underivatized amino acid as the template

The preparation and characterization of electrosynthesized poly(o-phenylenediamine) (iPoPD) as a molecular imprinting material were studied by an in situ quartz crystal impedance method. The changes of delta f0, delta R1, delta L1 and delta C0 suggest that the polymer film was compact and rigid. The thickness shear mode (TSM) acoustic sensor modified with this material exhibits molecular recognition ability to the template molecule of DL-phenylalanine. In the range 2-20 mM, a linear relationship between the frequency shift delta f0 and logC was found from the calibration graph. Scatchard analysis of the relevant calibration graph offers information on the equilibrium of the binding interaction and the recognition sites. Using this electropolymerization technology, the preparation of the sensor was very simple and the reproducibility of preparation was very good. In particular, it offers possibilities for sensor miniaturization.     

Expression and intein-mediated purification of novel staphylokinase SakSTAR with reduced immunogenicity and antiplatelet and antithrombin activation

In an effort to combine the benefits of fibrinolytics, such as staphylokinase (Sak), with those of thrombin inhibitors for the prevention of vessel reocclusion after vascular injury, we produced chimeric protein with plasminogen activator and thrombin-inhibiting properties. This fusion protein was a construct consisting of Sak (SakSTAR) lengthened about 36 amino acids from the C-terminus end of hirudin. We inserted 16 point mutations into the sequence of the gene encoding SakSTAR for reduced antibody binding from 50% to about 17% and inserted two RGD sequences for antiplatelet activity. The inhibition rate of platelet aggregation was 27%. Moreover, we proposed an efficient method of expression and purification in which we used 16 mg/L of anEscherichia coli strain of this novel fusion protein and retained full biologic activities toward plasminogen and thrombin.     

A thin liquid film thickness shear mode bulk acoustic wave sensor for determination of Proteus mirabilis

A thickness shear mode bulk acoustic wave sensor coated with a thin liquid culture medium film was developed and applied to determine the concentration of Proteus mirabilis (P. mirabilis). Experiments demonstrated that there was a good linear relationship between the turning point time and the logarithm of the P. mirabilis concentration in the range 2.0 x 10(2)-2.0 x 10(6) cells ml(-1). The detection was fast and accurate because of the sharp turning point of the response due to the thin culture film on the sensor surface. Other problems concerning the experiments are discussed in detail.     

Rational design of peptide ligand for affinity chromatography of tissue-type plasminogen activator by the combination of docking and molecular dynamics simulations

Combined docking and molecular dynamics (MD) simulations are carried out for the rational design of affinity peptide ligand of tissue-type plasminogen activator (t-PA). Ten amino acids that have high affinity to three different regions of t-PA are identified by the amino acids location method on the basis of candidate pocket structure of t-PA. Then, 14 tetrapeptides are built and docked into the candidate pocket of t-PA. The absolute value of the D(score) calculated from the docking simulation is used to assess the affinity of a peptide for t-PA. Consequently, six tetrapeptides that have high D(score) values are selected and linked to a spacer arm of [NH(CH(2))(6)NH(2)] that is present on EAH Sepharose gel. The linked compounds are further evaluated by docking into the candidate pocket of t-PA. As a result, the tetrapeptide QDES with the highest D(score) value is selected. Molecular surface analysis with the MOLCAD program reveals that electrostatic interactions and hydrogen bonds (H-bonds) contribute to the affinity interactions between the tetrapeptide and t-PA. MD simulations indicate that QDES-t-PA complex keeps stable, and the distances between the carboxyl groups of Asp189, Gln192 and Asp194 and the charged amino group of glutamine change little. Moreover, all the nine H-bonds found in the docking simulation are confirmed by the MD simulations. It is also found that three water molecules act as bridges between the ligand and the protein pocket by hydrogen bonding. Finally, high binding affinity and specificity of the peptide ligand are confirmed by the purification of t-PA from crude porcine heart extract using the immobilized-ligand column for affinity chromatography.     

Solid-phase Synthesis of Acyl-plasminogen-Streptokinase Activator Composite（APSAC） and Its Thrombolytic Properties

The dialysis method has been traditionally used for the conversion of native human plasminogen (Glu-Hpg) to lys-plasminogen(Lys-Hpg). Here is described a solid-phase synthesis method for the preparation of an acyl-plasminogen-streptokinase activator complex(APSAC) from Lys-Hpg, streptokinase (SK) and chemical modification agent(4-amidinophenyl-4‘-aminobenzoate hydrochloride) with the L-lysine-Sepharose 4B Column as the carrier. The new method significantly increases the product yield and purity over the liquidphase methods. The APSAC prepared with the new method exhibits a significant thrombolytic effect with a long half-life of about 8.8 h in rabbits.     

Surface immobilisation and properties of smooth muscle cells monitored by on-line acoustic wave detector

The attachment of rat aortic smooth muscle cells to various surfaces has been monitored by a thickness shear mode acoustic wave device incorporated into an on-line configuration. Using the total injection analysis method, laminin and fibronectin were adsorbed to the device surface, to be followed by introduction of cells into the system. The results of these experiments in terms of frequency and motional resistance measurements were also compared with those for cell attachment to the bare gold electrode of the sensor. The responses of the surface-bound cells to the introduction of various ions, depolarisation events and damage subsequent to exposure to hydrogen peroxide were also observed. Morphological changes in the cells, as confirmed by scanning electron microscopy, are correlated with results of the acoustic wave measurements.     

Pharmacokinetics in chimpanzees of recombinant human tissue-type plasminogen activator produced in mouse C127 and Chinese hamster ovary cells

Pharmacokinetics of recombinant tissue-type plasminogen activator (rt-PA) produced in mouse C127 cells (t-PA(C127] and Chinese hamster ovary cells (t-PA(CHO] was investigated in chimpanzees. rt-PA was administered via a constant rate i.v. infusion for 60 min, and t-PA concentration and activity in plasma were measured during and after infusion. The noncompartmental parameters were calculated according to the moment analysis method, and a population pharmacokinetic analysis was performed to obtain the mean and interindividual variability of the pharmacokinetic parameters. The mean residence time of t-PA(C127) was significantly longer and the total body clearance was significantly less than that of t-PA(CHO). t-PA(C127) has an alpha-galactosyl moiety in its carbohydrate chains, whereas such a structure is not found in t-PA(CHO). These results demonstrate that two preparations of rt-PA's with different carbohydrate structures show different pharmacokinetics, and suggest that the carbohydrate structure can affect the efficiency of hepatic uptake of t-PA. A possible mechanism is an interaction of t-PA(C127) with the natural anti-alpha-galactosyl antibody. The anti-alpha-galactosyl antibody level in plasma decreased in association with the plasma levels of t-PA(C127) but was unaffected by t-PA(CHO) levels.     

Specificity of human natural antibody to recombinant tissue-type plasminogen activator (t-PA) expressed in mouse C127 cells

A natural antibody with binding specificity for recombinant tissue-type plasminogen activator (t-PA) expressed in mouse C127 cells was present in almost all disease-free humans and patients with thrombotic disease examined. This antibody was specific for a carbohydrate, alpha 1-3-linked galactose residue, and was isolated by affinity chromatography using Synsorb 90 coupled with the glycosidic epitope Gal alpha 1-3Gal beta 1-4Glc-R as an immunoadsorbent. The evaluation of various glycoproteins for ability to bind the purified antibody in ELISA demonstrated that not only recombinant t-PA from C127 cells but also recombinant erythropoietin (EPO) and recombinant protein C produced in C127 cells have alpha 1-3-linked galactose residues on their sugar side chains. This anti-alpha-galactosyl antibody also interacted with natural t-PA from human vascular trees (vascular t-PA) and placenta (placenta t-PA), but not to melanoma t-PA, recombinant t-PA, EPO or protein C expressed in Chinese hamster ovary (CHO) cells.     

Diffusional transport of urokinase and acyl-urokinase into fibrin and plasma clots: time of contact and fibrinolytic response in vitro

The effect of short-time contacts (2—20 min) of fibrin and plasma clots with solutions of urokinase and acyl-urokinase in a buffer or human blood plasma on the degree and duration of fibrinolysis was studied in vitro. Both plasminogen activators readily diffuse into clots in these time intervals and initiate prolonged dose-dependent lysis of washed fibrin clots devoid of plasma inhibitors. In a plasma clot—plasma system containing inhibitors, the fibrinolytic action of urokinase that penetrated is rapidly suppressed. Acyl-urokinase that penetrated into plasma clots supports prolonged thrombolysis in the absence of an activator in the surrounding plasma due to its resistance to the action of inhibitors and slow reactivation (k _deac = 6·10^–5 s^–1).     

High-performance chromatographic method for the purification of tissue-type plasminogen activator

High-performance affinity chromatography was performed on five ligand-bound columns in an attempt to purify tissue-type plasminogen activator (t-PA), which is a glycoprotein with a high affinity for fibrin and also has two Kringle structures and finger-domain in its molecule. The five columns were concanavalin A-5PW, p-aminobenzamidine-5PW, imidinodiacetic acid-5PW, boric acid-5PW and lysine-5PW. All five were able to rapidly separate t-PA from contaminating proteins, with high resolution and recovery.     

Cloning and Expression of Functional Full-Length Human Tissue Plasminogen Activator in <Emphasis Type="Italic">Pichia pastoris</Emphasis>

Human tissue plasminogen activator (t-PA) plays a pivotal role in the treatment of acute myocardial infarction, ischemic stroke, and deep vein thrombosis. It has the benefit of generating no adverse effects such as fibrinogen depletion, systemic hemorrhage, and immunologic reactions. Human t-PA is a serine-protease enzyme containing 527 amino acid residues in five structural domains. The correct folding of t-PA requires the correct pairing of 17 disulfide bridges in the molecule. A gene encoding full-length human t-PA was cloned into pPICZαA expression vector downstream of alcohol oxidase promoter and α-mating signal sequence from Saccharomyces cerevisiae and flush with the kex2 cleavage site to express the protein with a native N terminus. The methylotrophic yeast, Pichia pastoris GS115 strain, was transformed with this cassette, and methanol utilizing (mut+) transformants were selected for production and secretion of human t-PA into culture media. SDS–PAGE and Western blot analysis showed the expressed bands of t-PA protein. Zymography test indicated suitable folding and proper function of the expressed recombinant human t-PA in conversion of plasminogen to plasmin and gelatin lysis. Amidolytic activity test showed the amidolytic activity of 1,650 IU/ml. The results of this study concluded that P. pastoris methylotrophic yeast can be a suitable alternative for mammalian and prokaryotic expression systems to produce t-PA.     

A comparison of bovine serum albumins, modified with a variety of carboxyl group agents, as stimulators of tissue-type plasminogen activator-catalyzed activation of plasminogen

Bovine serum albumins (BSA), modified with a variety of carboxyl group agents, stimulated the tissue-type plasminogen activator (t-PA)-catalyzed activation of human plasminogen. Modification with taurine (tau) and putrescine (put) provided the best stimulants. The tauBSA and putBSA were effective at a concentration of 5 micrograms/ml and enhanced the Lys-plasminogen activation by two-chain t-PA in a dose-dependent manner to a maximum of 44- to 46-fold at 200 micrograms/ml. The Km values for the activation of Glu-plasminogen by t-PA in the presence of tauBSA and putBSA (100 micrograms/ml) were 1.7 and 1.8 microM, while the kcat values were 0.059 and 0.062 s-1, respectively. T-PA was bound to both tauBSA and putBSA, which were immobilized on agarose beads, with KD values of 163 and 138 nM, respectively. The two modified BSAs were good substrates for plasmin and were hydrolyzed by the enzyme to small peptides. All of these modified BSA-related actions were inhibited by lysine analogs (e.g. tranexamic acid) which were adjusted to the concentrations required for the inhibition of the plasminogen (Kringle 1 domain) binding to fibrin. On the other hand, acetylation or succinylation of the amino groups of BSA was not effective, while alkylation of the thiol groups of this protein resulted in a moderate stimulation of the plasmin generation. The present results show that t-PA and plasminogen form complexes with certain charge-modified BSAs via their lysine-binding sites. The different stimulation potency of modified BSAs may provide a model for in vivo counterparts of fibrin.     

Fibrinolysis and thrombosis of fibrinogen-modified gold nanoparticles for detection of fibrinolytic-related proteins

Fibrinolysis (plasmin-mediated cleavage of fibrin structures) is a process in which fibrin clots can be removed from blood vessels, allowing the return of normal vascular function. Although several methods have been developed to measure plasmin activity and plasminogen (the plasmin precursor) concentrations, they are only moderately sensitive and quantitative and require large amounts of reagents, limiting their applicability. We developed two simple, label-free homogeneous assays using gold nanoparticles (Au NPs) for detection of fibrinolysis-related proteins and their activator (urokinase that converts plasminogen to plasmin) and inhibitor (α₂-plasmin inhibitor that inhibits plasmin and plasminogen bound to fibrin). We used a fibrinolysis-based sensor, based on plasmin-mediated cleavage of fibrinogen-modified Au NPs (Fib-Au NPs) leading to aggregation of Au NPs, to determine plasmin activity in a biological medium mimic solution. A combination of thrombin (Thr) and Fib-Au NPs allowed us to analyze plasmin activity and plasminogen concentrations in serum through Thr-induced agglutination of Fib-Au NPs. The limit of detection (LOD; S/N = 3) of this sensor for plasmin in serum was 0.4 nM (ca. 1.7 × 10⁻⁴ unit mL⁻¹). These label-free assays offer several advantages over conventional assays, including allowing rapid and simple readings with the naked eye or measurement by UV–vis absorption spectroscopy.